- Stocks
- Pharma & Healthcare
- AstraZeneca Pharma India
AstraZeneca Pharma India share price
NSE: ASTRAZENPharma & HealthcareDrug Manufacturers - Specialty & Generic
AstraZeneca Pharma India at a glance
AstraZeneca Pharma India (NSE: ASTRAZEN) closed at ₹6,055.50 on 21 Oct 2026, down 0.30% on the day. With a market capitalisation of ₹15,139 Cr, it ranks 425th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 80.9× trailing earnings, against a return on equity of 15.0% in FY25. Over the past year the share price has fallen 34.3%. Its 52-week range is ₹5,640.00 (9 Oct 2026) to ₹9,849.50 (3 Nov 2025); the last close is 38.5% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹579 Cr (+20.4% year on year) and net profit ₹45 Cr (−23.0%), on a standalone basis. Promoters held 75.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹15,139 CrRank 425 on NSE
- P/E (trailing)
- 80.9×
- Price to book
- 27.93×FY25
- EPS (TTM)
- ₹75.01to Q4 FY26
- ROE
- 15.0%FY25
- ROCE
- 31.2%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 6.7%FY25
- Book value / share
- ₹308.14FY25
- Dividend payout
- 51.8%FY25
- 52-week high
- ₹9,849.503 Nov 2025
- 52-week low
- ₹5,640.009 Oct 2026
- 1-year return
- −34.3%
- RSI (14-day)
- 38.8
Returns to 21 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.30% | +2.6% | −9.9% | −25.1% | −34.3% |
AstraZeneca Pharma India quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹388 Cr | ₹408 Cr | ₹440 Cr | ₹480 Cr | ₹526 Cr | ₹559 Cr | ₹612 Cr | ₹579 Cr |
| Revenue YoY | +31.2% | +31.2% | +44.0% | +25.4% | +35.8% | +37.0% | +38.9% | +20.4% |
| Net profit | −₹12 Cr | ₹38 Cr | ₹31 Cr | ₹58 Cr | ₹56 Cr | ₹54 Cr | ₹33 Cr | ₹45 Cr |
| Net profit YoY | −121.9% | −26.6% | +95.3% | +47.5% | — | +41.1% | +5.6% | −23.0% |
| Net margin | −3.0% | 9.4% | 7.0% | 12.1% | 10.6% | 9.7% | 5.3% | 7.8% |
| EPS | −₹4.72 | ₹15.37 | ₹12.34 | ₹23.30 | ₹22.33 | ₹21.69 | ₹13.04 | ₹17.95 |
AstraZeneca Pharma India financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹832 Cr | ₹814 Cr | ₹806 Cr | ₹1,003 Cr | ₹1,296 Cr | ₹1,716 Cr |
| Operating profit | ₹114 Cr | ₹127 Cr | ₹83 Cr | ₹174 Cr | ₹203 Cr | ₹253 Cr |
| Net profit | ₹72 Cr | ₹93 Cr | ₹62 Cr | ₹99 Cr | ₹162 Cr | ₹116 Cr |
| EPS (₹) | ₹28.90 | ₹37.30 | ₹24.60 | ₹39.70 | ₹64.60 | ₹46.30 |
| Cash from operations | ₹87 Cr | ₹105 Cr | ₹101 Cr | ₹58 Cr | ₹28 Cr | ₹65 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹364 Cr | ₹456 Cr | ₹511 Cr | ₹589 Cr | ₹712 Cr | ₹770 Cr |
AstraZeneca Pharma India shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| Foreign institutions | 2.89% | 3.03% | 2.74% | 2.71% | 2.78% | 2.68% |
| Domestic institutions | 4.65% | 4.56% | 5.26% | 5.56% | 5.80% | 6.08% |
| Non-institutions | 17.46% | 17.41% | 17.00% | 16.73% | 16.42% | 16.24% |
AstraZeneca Pharma India vs peers
The listed Pharma & Healthcare companies nearest to AstraZeneca Pharma India by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SYNGENESyngene International | ₹389.35 | −2.42% | −38.5% | ₹15,717 Cr | 49.4 | 6.5% |
| ERISEris Lifesciences | ₹1,129.50 | +1.31% | −29.8% | ₹15,652 Cr | 24.9 | 15.9% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −1.75% | −17.2% | ₹15,430 Cr | 22.9 | 11.2% |
| ALIVUSAlivus Life Sciences | ₹1,252.00 | −0.46% | +35.1% | ₹15,367 Cr | 27.3 | 17.2% |
| POLYMEDPoly Medicure | ₹1,502.40 | −3.07% | −19.4% | ₹15,228 Cr | 47.4 | 10.4% |
| ASTRAZENAstraZeneca Pharma India | ₹6,055.50 | −0.30% | −34.3% | ₹15,139 Cr | 80.9 | 15.0% |
| JUBLPHARMAJubilant Pharmova | ₹922.00 | −2.18% | −16.1% | ₹14,686 Cr | 36.7 | 13.4% |
Ask anything about AstraZeneca Pharma India
Pivot answers on the live chart with evidence you can check, and tests strategies against ASTRAZEN's own history. Try: “Why has ASTRAZEN moved over the last three months?” · “Backtest a 50-day moving-average crossover on ASTRAZEN over five years” · “Compare ASTRAZEN with SYNGENE on margins and valuation”
Frequently asked questions about AstraZeneca Pharma India
What is the share price of AstraZeneca Pharma India today?
AstraZeneca Pharma India (NSE: ASTRAZEN) last closed at ₹6,055.50 on 21 Oct 2026. Its 52-week high is ₹9,849.50 and its 52-week low is ₹5,640.00.
What is the market cap of AstraZeneca Pharma India?
AstraZeneca Pharma India's market capitalisation is ₹15,139 Cr (₹15,139 Cr) at the 21 Oct 2026 close, ranking 425th among the NSE companies Pivot tracks.
What is the P/E ratio of AstraZeneca Pharma India?
AstraZeneca Pharma India trades at a trailing P/E of 80.9. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 36.7.
What is the ROE and ROCE of AstraZeneca Pharma India?
Return on equity was 15.0% in FY25 and return on capital employed was 31.2% in FY25 (standalone figures).
Is AstraZeneca Pharma India a debt-free company?
AstraZeneca Pharma India is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What were AstraZeneca Pharma India's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), AstraZeneca Pharma India reported revenue of ₹579 Cr, +20.4% year on year, and net profit of ₹45 Cr, −23.0% year on year.
How has AstraZeneca Pharma India stock performed over the last year?
AstraZeneca Pharma India's share price has fallen 34.3% over the past year, −25.1% over three months and −9.9% over one month, to the 21 Oct 2026 close.
What is the shareholding pattern of AstraZeneca Pharma India?
As of 30 Jun 2026: promoters 75.00%, foreign institutions 2.68%, domestic institutions 6.08%, non-institutions 16.24%.
Who are AstraZeneca Pharma India's competitors?
The listed Pharma & Healthcare companies closest to AstraZeneca Pharma India by market cap are Syngene International, Eris Lifesciences, Alembic Pharmaceuticals, Alivus Life Sciences, Poly Medicure and Jubilant Pharmova.
Is AstraZeneca Pharma India a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out AstraZeneca Pharma India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTRAZEN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 21 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text